Professor Michael Jung has been elected as a 2014 NAI Fellow by the National Academy of Inventors.
The NAI Fellows Program has 414 Fellows worldwide representing more than 150 prestigious universities and governmental and non-profit research institutions. Collectively, the Fellows hold nearly 14,000 issued U.S. patents. This professional distinction is bestowed upon academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.
A world-renowned authority on synthetic organic and medicinal chemistry, Jung has more than 55 patents and/or patent applications arising from his research and consulting activities. He is a co-inventor of Xtandi®, an effective new therapy for patients with metastatic castration-resistant prostate cancer who no longer respond to medical or surgical treatments, and ARN-509, a drug in phase 3 clinical trials for non-metastatic, castration-resistant prostate cancer.
The NAI Fellows will be inducted on Mar. 20, 2015, as part of the 4th Annual Conference of the National Academy of Inventors at the California Institute of Technology in Pasadena. U.S. Patent and Trademark Office (USPTO) Deputy Commissioner for Patent Operations Andrew Faile will be providing the keynote address for the induction ceremony. Fellows will be presented with a special trophy, newly designed medal, and rosette pin in honor of their outstanding accomplishments.